Sophie Rivière

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Sophie Dupuis‐Girod, Isabelle Ginon, Jean‐Christophe Saurin et al. · JAMA · 2012 · 378 citations

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Pierre Charles, Benjamin Terrier, Élodie Perrodeau et al. · Annals of the Rheumatic Diseases · 2018 · 325 citations

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

Hélène Vallet, Sophie Rivière, Alice Sanna et al. · Journal of Autoimmunity · 2015 · 212 citations · Full text

Inflammation, Rheumatology, Autoimmune Disease +9

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

Hélène Vallet, P. Sève, Lucie Biard et al. · Arthritis & Rheumatology · 2016 · 170 citations · Full text

Molecular screening of<i>ALK1/ACVRL1</i>and<i>ENG</i>genes in hereditary hemorrhagic telangiectasia in France

Gaëtan Lesca, Henri Plauchu, Florence Coulet et al. · Human Mutation · 2004 · 119 citations